{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:37:33Z","timestamp":1778603853055,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,12]]},"DOI":"10.7759\/cureus.62227","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T11:31:32Z","timestamp":1718191892000},"source":"Crossref","is-referenced-by-count":1,"title":["Rituximab Therapy for Immune-Mediated Neurological Diseases: Our Experience at a Tertiary Care Centre"],"prefix":"10.7759","author":[{"given":"Pranit D","family":"Khandait","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalesh","family":"Rohatgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish P","family":"Nirhale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajwal M","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravin U","family":"Naphade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616666741","article-title":"Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management","volume":"10","author":"Bittner S","year":"2017","unstructured":"Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2017, 10:51-66. 10.1177\/1756285616666741","journal-title":"Ther Adv Neurol Disord"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.29105","article-title":"Rituximab: how approval history is reflected by a corresponding patent filing strategy","volume":"6","author":"Storz U","year":"2014","unstructured":"Storz U. Rituximab: how approval history is reflected by a corresponding patent filing strategy. MAbs. 2014, 6:820-37. 10.4161\/mabs.29105","journal-title":"MAbs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler G","year":"1975","unstructured":"K\u00f6hler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975, 256:495-7. 10.1038\/256495a0","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20547","article-title":"Human peripheral blood B-cell compartments: a crossroad in B-cell traffic","volume":"78","author":"Perez-Andres M","year":"2010","unstructured":"Perez-Andres M, Paiva B, Nieto WG, et al.. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom. 2010, 78:S47-60. 10.1002\/cyto.b.20547","journal-title":"Cytometry B Clin Cytom"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi R","year":"2007","unstructured":"Magliozzi R, Howell O, Vora A, et al.. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007, 130:1089-104. 10.1093\/brain\/awm038","journal-title":"Brain"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer J","year":"2016","unstructured":"Salzer J, Svenningsson R, Alping P, et al.. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology. 2016, 87:2074-81. 10.1212\/WNL.0000000000003331","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree BA","year":"2005","unstructured":"Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005, 64:1270-2. 10.1212\/01.WNL.0000159399.81861.D5","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato V","year":"2016","unstructured":"Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016, 73:1342-8. 10.1001\/jamaneurol.2016.1637","journal-title":"JAMA Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.08.009","article-title":"Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis","volume":"35","author":"Huang W","year":"2019","unstructured":"Huang W, Wang L, Zhang B, Zhou L, Zhang T, Quan C. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis. Mult Scler Relat Disord. 2019, 35:246-52. 10.1016\/j.msard.2019.08.009","journal-title":"Mult Scler Relat Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan S","year":"2018","unstructured":"Ramanathan S, Mohammad S, Tantsis E, et al.. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018, 89:127-37. 10.1136\/jnnp-2017-316880","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12461","article-title":"Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first-line therapy","volume":"26","author":"Fatehi F","year":"2021","unstructured":"Fatehi F, Okhovat AA, Panahi A, Ziaaddini B, Rajabally YA, Nafissi S. Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first-line therapy. J Peripher Nerv Syst. 2021, 26:469-74. 10.1111\/jns.12461","journal-title":"J Peripher Nerv Syst"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2018.10.007","article-title":"Efficacy and safety of rituximab in vasculitic neuropathy: a systematic review of the literature","volume":"15","author":"Mena-V\u00e1zquez N","year":"2019","unstructured":"Mena-V\u00e1zquez N, Cabezudo-Garc\u00eda P, Fuego Varela C, Manrique-Arija S, Fernandez-Nebro A. Efficacy and safety of rituximab in vasculitic neuropathy: a systematic review of the literature. Reumatol Clin (Engl Ed). 2019, 15:173-8. 10.1016\/j.reuma.2018.10.007","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja F","year":"2000","unstructured":"Zaja F, Russo D, Fuga G, Perella G, Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology. 2000, 55:1062-3. 10.1212\/wnl.55.7.1062-a","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study","volume":"98","author":"Nowak RJ","year":"2022","unstructured":"Nowak RJ, Coffey CS, Goldstein JM, et al.. Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology. 2022, 98:e376-89. 10.1212\/WNL.0000000000013121","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl F","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, et al.. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 2022, 79:1105-12. 10.1001\/jamaneurol.2022.2887","journal-title":"JAMA Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.1951","article-title":"Clinical and laboratory remission with rituximab treatment in anti-MuSK-positive myasthenia gravis patients (P6-13.007)","volume":"3","author":"Berin Inan","year":"2022","unstructured":"Berin Inan, Can Ebru Bekircan-Kurt, Sevim Erdem-Ozdamar, Ersin Tan. Clinical and laboratory remission with rituximab treatment in anti-MuSK-positive myasthenia gravis patients (P6-13.007). Neurology. 2022, 3:1951. 10.1212\/WNL.98.18_supplement.1951","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.004","article-title":"Muscle-specific tyrosine kinase and myasthenia gravis owing to other antibodies","volume":"36","author":"Rivner MH","year":"2018","unstructured":"Rivner MH, Pasnoor M, Dimachkie MM, Barohn RJ, Mei L. Muscle-specific tyrosine kinase and myasthenia gravis owing to other antibodies. Neurol Clin. 2018, 36:293-310. 10.1016\/j.ncl.2018.01.004","journal-title":"Neurol Clin"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.25259\/JNRP_59_2022","article-title":"Therapeutic response to rituximab in seropositive neuromyelitis optica: experience from a tertiary care center in South India","volume":"14","author":"James J","year":"2023","unstructured":"James J, Gafoor VA, Jose J, Smita B, Balaram N. Therapeutic response to rituximab in seropositive neuromyelitis optica: experience from a tertiary care center in South India. J Neurosci Rural Pract. 2023, 14:327-32. 10.25259\/JNRP_59_2022","journal-title":"J Neurosci Rural Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14158","article-title":"The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: a real-world study from Turkey","volume":"75","author":"Uzunk\u00f6pr\u00fc C","year":"2021","unstructured":"Uzunk\u00f6pr\u00fc C, T\u00fct\u00fcnc\u00fc M, G\u00fcnd\u00fcz T, et al.. The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: a real-world study from Turkey. Int J Clin Pract. 2021, 75:e14158. 10.1111\/ijcp.14158","journal-title":"Int J Clin Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: a meta-analysis","volume":"19","author":"Gao F","year":"2019","unstructured":"Gao F, Chai B, Gu C, Wu R, Dong T, Yao Y, Zhang Y. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol. 2019, 19:36. 10.1186\/s12883-019-1261-2","journal-title":"BMC Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara M","year":"20201","unstructured":"Tahara M, Oeda T, Okada K, et al.. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 20201, 19:298-306. 10.1016\/S1474-4422(20)30066-1","journal-title":"Lancet Neurol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577812","article-title":"Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): a systematic review and meta-analysis","volume":"364","author":"Nepal G","year":"2022","unstructured":"Nepal G, Kharel S, Coghlan MA, Rayamajhi P, Ojha R. Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): a systematic review and meta-analysis. J Neuroimmunol. 2022, 364:577812. 10.1016\/j.jneuroim.2022.577812","journal-title":"J Neuroimmunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103044","article-title":"A comparison of the effects of rituximab versus other immunotherapies for MOG-IgG-associated central nervous system demyelination: a meta-analysis","volume":"53","author":"Bai P","year":"2021","unstructured":"Bai P, Zhang M, Yuan J, Zhu R, Li N. A comparison of the effects of rituximab versus other immunotherapies for MOG-IgG-associated central nervous system demyelination: a meta-analysis. Mult Scler Relat Disord. 2021, 53:103044. 10.1016\/j.msard.2021.103044","journal-title":"Mult Scler Relat Disord"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease","volume":"99","author":"Barreras P","year":"2022","unstructured":"Barreras P, Vasileiou ES, Filippatou AG, et al.. Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease. Neurology. 2022, 99:e2504-16. 10.1212\/WNL.0000000000201260","journal-title":"Neurology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102585","article-title":"Efficacy and safety of rituximab in treating patients with multiple sclerosis (MS): a systematic review and meta-analysis","volume":"19","author":"Ghajarzadeh M","year":"2020","unstructured":"Ghajarzadeh M, Azimi A, Valizadeh Z, Sahraian MA, Mohammadifar M. Efficacy and safety of rituximab in treating patients with multiple sclerosis (MS): a systematic review and meta-analysis. Autoimmun Rev. 2020, 19:102585. 10.1016\/j.autrev.2020.102585","journal-title":"Autoimmun Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser SL","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, et al.. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008, 358:676-88. 10.1056\/NEJMoa0706383","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001088","article-title":"Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the GENERATE Registry","volume":"8","author":"Thaler FS","year":"2021","unstructured":"Thaler FS, Zimmermann L, Kammermeier S, et al.. Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the GENERATE Registry. Neurol Neuroimmunol Neuroinflamm. 2021, 8:10.1212\/NXI.0000000000001088","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13291","article-title":"Efficacy and safety of rituximab in autoimmune encephalitis: a meta-analysis","volume":"142","author":"Nepal G","year":"2020","unstructured":"Nepal G, Shing YK, Yadav JK, Rehrig JH, Ojha R, Huang DY, Gajurel BP. Efficacy and safety of rituximab in autoimmune encephalitis: a meta-analysis. Acta Neurol Scand. 2020, 142:449-59. 10.1111\/ane.13291","journal-title":"Acta Neurol Scand"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.5986","article-title":"AB0846 Efficacy of rituximab in idiopathic inflammatory myopathies. Experience on 36 patients from a prospective monocentric cohort","volume":"82","author":"Gamba A","year":"2023","unstructured":"Gamba A, Iaccarino L, Cocconcelli E, et al.. AB0846 Efficacy of rituximab in idiopathic inflammatory myopathies. Experience on 36 patients from a prospective monocentric cohort. Ann Rheum Dis. 2023, 82:1636. 10.1136\/annrheumdis-2023-eular.5986","journal-title":"Ann Rheum Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051609","article-title":"Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis","volume":"13","author":"Zhen C","year":"2022","unstructured":"Zhen C, Hou Y, Zhao B, Ma X, Dai T, Yan C. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Front Immunol. 2022, 13:1051609. 10.3389\/fimmu.2022.1051609","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/259610-rituximab-therapy-for-immune-mediated-neurological-diseases-our-experience-at-a-tertiary-care-centre","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T11:31:37Z","timestamp":1718191897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/259610-rituximab-therapy-for-immune-mediated-neurological-diseases-our-experience-at-a-tertiary-care-centre"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.62227","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,12]]}}}